Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : TELK -- Telik, Inc. -- Ignore unavailable to you. Want to Upgrade?

To: tommysdad who wrote (51)	12/15/2000 2:32:16 AM
From: scaram(o)uche	Read Replies (1) \| Respond to of 887

Thanks, useful info. Do you subscribe to a database that covers all projects/investigators, or is that one just close to home? A very weak area of mine, and actually getting weaker.... pharma competitive projects. I need to start my own database. I used to have extensive files in my mail program, cross-filed for companies (pharmas and biotechs) and indications. However..... change computers, change mail programs, get lazy, and..... poof. It's a project for next year.

To: tommysdad who wrote (51)	12/15/2000 7:09:18 PM
From: scaram(o)uche	Read Replies (1) \| Respond to of 887

To clarify, for those watching..... we know that TELK has a MCP-1 antagonist lead molecule that is active in an animal model. The MCP-1 receptor (or a MCP-1 receptor) is CCR2, a G-protein-coupled receptor. Other companies with an interest in this field include MLNM, Pfizer and Roche. TD will be along soon to add to the list. <g> We've already discussed CCR1, which is a receptor for MIP-1 alpha. Status at TELK is lead optimization, last report that I know of (no report of activity in an animal model).